• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

[Pharmacokinetics and metabolism of gallopamil].

作者信息

Eichelbaum M

机构信息

Dr. Margarete Fischer-Bosch-Institut für Klinische Pharmakologie, Stuttgart.

出版信息

Z Kardiol. 1989;78 Suppl 5:20-4.

PMID:2631477
Abstract

Despite its almost complete absorption following oral administration, gallopamil has an absolute bioavailability of only 15% due to an extensive hepatic first-pass metabolism. During multiple oral dosing bioavailability increases to approximately 25% indicating a partial saturation of first-pass metabolism. Since the half-life time of gallopamil is on average 3-6 h a minimum of three times daily dosing of the instant-release 50 mg tablet is required in order to maintain therapeutic plasma concentrations. The sustained-release 100 mg tablet which recently became available has a relative bioavailability comparable to the instant release preparation. Due to the delayed drug liberation therapeutic plasma concentrations are maintained for 24 h following once or twice daily administration of this drug preparation.

摘要

相似文献

1
[Pharmacokinetics and metabolism of gallopamil].
Z Kardiol. 1989;78 Suppl 5:20-4.
2
Bioavailability of theophylline from a sustained-release aminophylline formulation (Euphyllin retard tablets)--plasma levels after single and multiple oral doses.来自缓释氨茶碱制剂(优喘平缓释片)的茶碱生物利用度——单次和多次口服给药后的血浆水平
Int J Clin Pharmacol Ther Toxicol. 1981 May;19(5):223-7.
3
Complete bioavailability and lack of food-effect on pharmacokinetics of gliclazide 30 mg modified release in healthy volunteers.健康志愿者中30毫克缓释格列齐特的生物利用度及食物对其药代动力学影响的研究 (注:该翻译表述更完整准确,符合医学文献标题翻译习惯,与原文简洁表述的意思一致) 完整生物利用度及食物对健康志愿者中30毫克缓释格列齐特药代动力学无影响 (更符合你的要求格式)
Biopharm Drug Dispos. 2002 May;23(4):151-7. doi: 10.1002/bdd.303.
4
Estimating mass balance for inhaled drugs in humans: an example with a VLA-4 antagonist, IVL745.估算人类吸入药物的质量平衡:以VLA - 4拮抗剂IVL745为例。
J Clin Pharmacol. 2004 Apr;44(4):348-58. doi: 10.1177/0091270004263465.
5
Pre-clinical pharmacokinetics of the cyclooxygenase-inhibiting nitric oxide donor (CINOD) AZD3582.环氧合酶抑制性一氧化氮供体(CINOD)AZD3582的临床前药代动力学
J Pharm Pharmacol. 2005 May;57(5):587-97. doi: 10.1211/0022357056028.
6
Pharmacokinetics and absolute bioavailability of epristeride in healthy male subjects.
Biopharm Drug Dispos. 1996 Apr;17(3):249-58. doi: 10.1002/(SICI)1099-081X(199604)17:3<249::AID-BDD952>3.0.CO;2-E.
7
Bioequivalency of three tableted gallopamil products.
Boll Chim Farm. 1989 May;128(5):173-6.
8
Pharmacokinetics and pharmacodynamics of the enantiomers of gallopamil.
J Pharmacol Exp Ther. 1997 Jun;281(3):1102-12.
9
Pharmacokinetics and pharmacodynamics of the acetylcholinesterase inhibitor 2,2,2-trifluoro-1-(3-trimethylsilylphenyl) ethanone in dog. Potential for transdermal patch delivery.乙酰胆碱酯酶抑制剂2,2,2-三氟-1-(3-三甲基硅基苯基)乙酮在犬体内的药代动力学和药效学。经皮贴剂给药的潜力。
Arzneimittelforschung. 1995 Dec;45(12):1245-52.
10
Pharmacokinetics of an oral once-a-day controlled-release oxybutynin formulation compared with immediate-release oxybutynin.每日一次口服控释奥昔布宁制剂与速释奥昔布宁的药代动力学比较。
J Clin Pharmacol. 1999 Mar;39(3):289-96.

引用本文的文献

1
Disposition, Elimination and Haemodynamic Effects of Gallopamil in Patients with Fatty Liver Disease.加洛帕米在脂肪肝疾病患者中的处置、消除及血流动力学效应
Clin Drug Investig. 1995 Dec;10(6):337-43. doi: 10.2165/00044011-199510060-00004.
2
Pharmacokinetics and pharmacodynamics of R- and S-gallopamil during multiple dosing.多次给药期间R-和S-加洛帕米的药代动力学和药效学
Br J Clin Pharmacol. 2000 Feb;49(2):132-8. doi: 10.1046/j.1365-2125.2000.00115.x.
3
Comparison of the potassium channel blocker tedisamil with the beta-adrenoceptor blocker esmolol and the calcium antagonist gallopamil in patients with coronary artery disease.
冠心病患者中钾通道阻滞剂替地沙米与β-肾上腺素能受体阻滞剂艾司洛尔及钙拮抗剂加洛帕米的比较。
Clin Cardiol. 1998 Jul;21(7):492-502. doi: 10.1002/clc.4960210708.
4
Clinical pharmacokinetics of vasodilators. Part I.血管扩张剂的临床药代动力学。第一部分。
Clin Pharmacokinet. 1998 Jun;34(6):457-82. doi: 10.2165/00003088-199834060-00003.
5
Gallopamil. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in ischaemic heart disease.加洛帕米。对其药效学和药代动力学特性以及在缺血性心脏病中的治疗潜力的综述。
Drugs. 1994 Jan;47(1):93-115. doi: 10.2165/00003495-199447010-00007.
6
Calcium antagonists and silent myocardial ischaemia.
Drugs. 1992;43 Suppl 1:15-20. doi: 10.2165/00003495-199200431-00005.